Sickle cell disease (SCD) is a congenital haemoglobinopathy that causes frequent acute care/emergency room visits and hospital admissions for affected individuals. Evidence from population-based studies demonstrating the role of hydroxycarbamide (HC, also termed hydroxyurea) in reducing hospital readmission rates is limited. Our objective was to describe the use of HC and its association with acute care utilization and readmission rates using a large, nationally-representative US health insurance claims database over a 6-year period between 2009 and 2014. We identified 20 721 SCDrelated inpatient and acute care encounters. Patients had been exposed to HC within 6 months prior to admission in 4263 (21%) of SCD-related admission events. HC use was more common among children aged 10-17 years and young adults aged 18-29 years. HC was associated with lower 30-day all-cause readmission rates in adults treated with average daily doses ≥1 g (odds ratio [OR], 0Á72, 95% confidence interval [CI] 0Á52-0Á99) and doses of 0Á5-1 g (OR, 0Á73, 95% CI 0Á57-0Á93), compared to HC treatment with average daily doses of <0Á5 g; adherence to HC with proportion of days covered of ≥0Á80 was also associated with significantly lower 30-day all-cause readmission risks (OR, 0Á59, 95% CI 0Á41-0Á84). Optimal therapeutic dosing and adherence to HC treatment significantly reduces 30-day readmissions among patients with SCD.
Introduction
Sickle cell disease (SCD) is an inherited autosomal recessive disorder of haemoglobin that, in the United States (US), primarily affects African Americans (Piel et al, 2017) . SCD is characterized by haemolytic anaemia, recurring acute painful crises and acute chest syndrome (ACS), which require immediate treatment in the emergency room (ER) and/or inpatient settings. Patients with SCD have high admission rates and ER visits caused by complications related to the disease. Thirty-day and 14-day readmission rates are as high as 33% and 22%, respectively, among SCD patients with the highest rates among 18-to 30-year-olds (Brousseau et al, 2010) . These frequent acute care encounters incur enormous financial burdens on health systems. It is estimated that annual management costs for SCD exceed $1Á1 billion in the US, with the majority of the costs (81%) attributable to inpatient admissions (Kauf et al, 2009) . Therefore, reducing hospital readmission rates is essential to ensuring quality care and mitigating the rising health care costs for individuals with SCD.
Addressing high rates of hospital readmission rates is a priority for continuous SCD care improvement. The 30-day readmission rate is increasingly recognized as a quality metric for SCD care. The National Association of Children's Hospital and Related Institutions (NACHRI) established the 30-day readmission rate as a benchmark for quality SCD care (Institute of Medicine (US). Committee on Quality of Health Care in America. 2001 ). In addition, this quality measure has been adopted by the Centers for Medicare and Medicaid Services (CMS) for adjusting reimbursement for inpatient services (Brock & Jencks, 2008) .
Hydroxycarbamide (HC, also termed hydroxyurea) is one of two medications approved by the US Food and Drug Administration (FDA) for SCD; the second medication, Endari â (L-glutamine oral powder), introduced in 2017, was the first approval for this rare blood disorder in nearly 20 years. HC has the potential of reducing complications of vaso-occlusive crises by reactivating fetal c-globin, improving nitric oxide (NO) metabolism, and reducing adhesion of sickled red blood cells to the vascular endothelial walls (Ware, 2010) . The laboratory and clinical efficacy of HC has been demonstrated in numerous randomized clinical trials and smaller observational studies in both paediatric and adult populations (Charache et al, 1992 (Charache et al, , 1995 Ferster et al, 1996; Jayabose et al, 1996; Scott et al, 1996; De Montalembert et al, 1997; Kinney et al, 1999) . Follow-up from the subjects enrolled in these trials showed salutary long-term benefits in morbidity, mortality, laboratory tests and preservation of organ function (McGann & Ware, 2011 . Several studies conducted in Italy, Belgium and India have shown significant clinical benefits attributable to HC (Jain et al, 2012; Nottage et al, 2013; Le et al, 2015; Colombatti et al, 2018) . However, these studies were limited with respect to the relatively small simple size, single institution design and shorter follow-up periods in randomized clinical trials. Moreover, evidence is lacking that demonstrates the clinical effectiveness of HC in real-world settings from the US (Lanzkron et al, 2006) , despite being cost-effective in the Multicenter Study of Hydroxyurea (MSH) (Moore et al, 2000) . There is growing evidence for the efficacy and safety of HC; yet, this treatment remains under-utilized (Mulaku et al, 2013; Ware et al, 2016) . One study of 312 US Medicaid enrolees with SCD demonstrated that adherence (medication possession ratio ≥0Á80) was associated with reduced risks of SCD-related hospitalization (hazard ratio [HR] = 0Á65), allcause and SCD-related ER visits (HR = 0Á72 and 0Á58), vasoocclusive events (HR = 0Á66) and reduced costs (Candrilli et al, 2011) . However, this study did not examine the outcomes of 30-day hospital readmission following SCD-related hospitalizations or associations with cumulative HC doses on hospitalization.
The objectives of this study were to use a large, nationally-representative US administrative claims database to document patterns of HC use in a population of commerciallyinsured SCD patients and investigate associations of cumulative therapeutic doses and adherence levels of HC in relation to 30-day readmission and acute-care utilization rates.
Methods

Data source
We conducted a retrospective cohort study utilizing data from the Truven Health MarketScan â Commercial Claims Databases include health insurance claims data in addition to enrolment data from large groups of participating US employers and health plans across all 50 states and Washington D.C. (Hansen, 2017) . The databases were linked to prescription drug claims and encounter data to provide individual-level inpatient, outpatient and pharmacy services for employees, their spouses and dependents. All data were de-identified and Health Insurance Portability and Accountability Act (HIPAA) of 1996 compliant. This study was approved by the Institution Review Board of the University of Illinois at Chicago.
Patient selection
All subjects with one or more medical claims from an inpatient discharge summary or ≥2 separate medical claims from outpatient services that were at least 30 days apart indicative of SCD using International Classification of Diseases, Ninth Revision, Clinical Modification; (ICD-9-CM) code (See Table SI) were initially selected for study inclusion. To ensure the homogeneity of cohort, patients with any claims for sickle cell trait during the follow-up period were excluded, as well as claims for any type of cancer, or undergoing a haematopoietic stem cell or solid organ transplantation. We applied an additional SCDidentifying algorithm (RuSH) to further specify SCD cases (Paulukonis et al, 2014) . All SCD-related admission events were defined as the occurrence of a diagnosis for any SCD-related condition in discharge summaries evidenced by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) codes (See Table SII ). Only admission events of patients who were continuously enrolled in the health plan for at least 6 months (180 days) before the admission date and at least 1 month (30 days) following discharge were selected. The discharge date was designated as the index date. Pharmacy dispensing claims for HC and other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opiate analgesics, were identified using relevant national drug codes on the outpatient prescription claims records. Under the participating health plans, a fixed co-payment of 5-8 US dollars is associated with each outpatient hydroxycarbamide prescription. Selection of patients for this analysis is summarized in Fig 1. 
Exposures
Using outpatient prescription drug records, we collected data on HC dispensed during the 6-month period preceding the admission events. We included only oral HC in the outpatient settings. To limit the effects of confounding by indication, we excluded all newly initiated HC occurring within 14 days prior to the admission dates of the SCD-related admissions. The proportion of days covered (PDC), one of the most commonly used and reproducible methods for determining medication adherence with administrative claims (Andrade et al, 2006) , was calculated for each SCD-related admission event to determine HC adherence in the 6-month baseline period (Karve et al, 2008) . For every admission event, the subject's exposure status to HC was examined daily in a time-dependent manner. Prescription refill dates and corresponding days' supply from pharmacy dispensing records were used to calculate PDC estimates. For example, if a patient with SCD refilled 2 HC prescriptions of 30 days' supply and 1 prescription of 90 days' supply over a 180 days' period, his adherence to hydroxycarbamide measured by PDC would be 0Á83 ((30 + 30 + 90)/180). If the patient had early refills during the baseline period or left-over from time before the baseline period, the number of days covered by HC were adjusted to account for overlap. SCD patients who had a PDC level above or equal to 0Á80 were considered to be highly adherent HC users, whereas SCD patients with a PDC between 0Á50 and 0Á80 were considered to be intermediate adherent users.
Hydroxycarbamide exposure patterns were defined as: (i) ever HC exposed compared to never HC exposed (main analyses limited to the whole cohort); (ii) higher-dose HC exposure (≥1 g average daily dose) and intermediate-dose HC exposure (<1 g and ≥0Á5 g daily dose) compared to lower-dose HC exposure (>0 mg and <0Á5 g daily dose, reference group); (iii) recent HC exposure (dispensing record included HC during the 3 months period prior to admission date) compared to not recently HC exposed; and (iv) highly adherent HC users (PDC ≥ 0Á80) and intermediate adherent HC users (0Á80 > PDC ≥ 0Á50) 
Outcome measures
The primary outcomes were SCD-related readmissions, allcause readmissions and presence of all-cause acute care encounters, defined as hospital admissions and/or ER visits. We evaluated the occurrence of these outcomes at both 7 and 30 days following discharge date. SCD-related readmissions were identified using the same criteria as primary SCDrelated admission events. Secondary outcomes included length of stay for the index admission event in addition to death at discharge.
Covariates
We measured multiple a priori covariates considered to be possible confounders for the relation between HC and readmission and acute care/ER visits. Patient demographics, such as age and sex, were measured at admission date. Presence of concomitant ACS, pneumonia and asthma were measured using ICD-9CM discharge diagnoses associated with the index admission (See Table SIII ). The presence of hospital admission and/or ER visits over the baseline period was determined by claims of inpatient and outpatient services. Erythrocyte transfusion events were identified using relevant ICD-9-CM diagnosis codes in addition to common procedure coding system codes documented among the administrative health insurance claims. Information on opioid medication doses was determined using pharmacy dispensing records and doses were converted to cumulative oral morphine equivalent (OME) using methods described previously (Han et al, 2016 (Han et al, , 2017 .
Statistical analysis
Differences in demographic and acute care utilization characteristics between HC exposure types were assessed using descriptive statistics. To compare groups, we used Student's t-test and Kruskal-Wallis test for continuous variables and chi-square test for categorical variables.
Multivariable regression models were used to assess the association between HC exposure with acute care utilization (readmission events and ER visits) in 7-day and 30-day timeframes. Generalized estimating equation models, assuming a first-order autoregressive covariance structure, were used to account for correlation of multiple SCD-related admission events contributed per individual patient. Multivariable models were adjusted for patient demographic and clinical attributes (age, gender, presence of admission and ER visit in the 6-month period preceding admission, past NSAIDs and opiate analgesics exposure, measured by cumulative OME), hospitalization characteristics (year and season of admission, weekend discharge, ACS and pneumonia diagnosis code, cooccurring asthma diagnosis code, erythrocyte transfusion and length of stay). Models were fit using terms on ever-exposure versus never-exposure using the whole analytical cohort. The impacts of other types of HC use patterns based on cumulative HC exposure, status of recent exposure and HC adherence on readmission and acute care services utilization rates were limited to the adult patients in the cohort. Odds ratios (OR) and 95% confidence intervals (CI) were estimated to determine the association between type of HC exposure and acute care utilization following discharge of the corresponding SCD-related hospitalization events. All analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC, USA); two-tailed P values <0Á05 were considered statistically significant.
Results
Overall, 20 721 hospitalizations involving 6926 patients with SCD met the inclusion criteria (Table I) The proportion rates of hospitalizations with HC exposure were highest in the 10-to 17-year-olds, followed by the 18-to 29-year-old group (Fig 2) . Figure 3 shows adherence rates to HC therapy by age group. Among SCD-related admissions associated with HC exposure, estimated PDC was higher in the youngest paediatric patients (0-9 years) at 0Á78 (0Á87) [mean (median)], while lowest adherence was observed in younger adult patients (18-29 years) at 0Á36 (0Á33) [mean (median)].
Patterns of HC use
Patients in 4263 (20Á6%) hospitalizations had been exposed to HC within 6 months prior to admission (Table II) . Among these primary admission events, 793 (18Á6%) had higher dose HC exposure, defined by an average daily dose of ≥1 g; 1354 (31Á8%) had intermediate dose HC exposure, defined by an average daily dose of 0Á5-1 g; and 2116 (49Á6%) had lower dose HC exposure (an average daily dose of <0Á5 g). HC-exposed admissions were more common among younger male patients and in more recent years in the study cohort. HC-exposed admission events were less likely to have ACS diagnosis at discharge. During the 6 months preceding admission, a greater proportion of HC exposed admissions had ≥1 emergency visits and ≥1 all-cause admissions. Further, HC exposed groups had a significantly higher proportion of erythrocyte transfusion during admission as well as a history of both opiate analgesics and NSAIDs. 
ACS, acute chest syndrome; ER, emergency room; HC, hydroxycarbamide; IQR, interquartile range; NSAIDs, Nonsteroidal anti-inflammatory drugs; SD, standard deviation. *High-dose hydroxycarbamide exposure defined by the median of the cumulative hydroxycarbamide dose among patients ever-exposed. Set at 90 g across age groups. Any patient with ≥90 g cumulative dose over the 180 days preceding the index admission event is considered as a highdose hydroxycarbamide user. † Weekend discharge status defined as Saturday and Sunday, while weekday discharge was Monday-Friday). ‡ Students t-test for comparing means across exposed groups. § Wilcoxon Rank sum test for comparing medians across exposed groups.
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HC adherence measured by PDC among admission events in adult patients (age ≥18 years) in relation to outcomes are reported in Table II . A total of 299 (9Á8%) of the SCDrelated admissions had high HC adherence (PDC ≥ 0Á80), 762 (24Á9%) had intermediate adherence to HC (0Á50 ≤ PDC < 0Á80) and 1999 (65Á3%) had low adherence 
Whole cohort (paediatric and adult patients) High adherent user (PDC ≥ 0Á80) 0Á54 0Á36-0Á82 0Á0034 0Á60 0Á45-0Á79 0Á0003 0Á52 0Á34-0Á78 0Á0019 0Á62 0Á47-0Á82 0Á0007 0Á51 0Á37-0Á70 
Reference
Analysis limited to adults, the outcome is SCD-related 30-day admission. Adjusted for age, gender, length of stay, cumulative opioids exposure (measured by oral morphine equivalent), nonsteroidal anti-inflammatory drugs exposure, transfusion during hospitalization, all-cause hospitalization in the previous 6 months, any Emergency Room visits in the previous 6 months, asthma diagnosis code, acute chest syndrome code, year of admission, season of admission and weekday of discharge. SCD, sickle cell disease; OR, odds ratio; CI, confidence interval; HC, hydroxycarbamide. *The ever-exposure term in this model can be interpreted as estimating the allocation bias between exposed and unexposed SCD patients. † Models comparing High (≥1g) and Intermediate (0.5g to <1g) cumulative daily HC doses to Low (>0g to <0.5g) cumulative daily HC doses in the 180-day period before the index admission event. ‡ Statistically significant at the P < 0Á05 level.
(PDC < 0Á50). A total of 2225 hospitalizations (72Á7%) had recent HC exposure, defined as presence of HC dispensing recording during the three months preceding admission, while 835 (27Á3%) had discontinued HC for more than 3 months at the time of SCD-related index hospitalizations.
Association of HC exposure with readmission
The unadjusted results demonstrated that HC unexposed admission events were associated with lower 30-day SCDrelated (18Á5% vs. 24Á3%, P < 0Á0001), all-cause readmissions (20Á8% vs. 25Á9%, P < 0Á001) and all-cause acute-care utilizations (31Á5% vs. 37Á1%, P < 0Á001) at 30 days after hospitalization (Table II) . No statistically significant differences were observed between exposed and unexposed groups at 7-day post-discharge. The mean length of stay was the same between the two groups (6Á05 vs. 6Á19 days, P = 0Á1228) and rates of inpatient mortality were similar, at 0Á2%. In subgroup analyses assessing cumulative HC dose with our endpoints, increasing doses were correlated with significantly lower readmission and acute care encounter rates at both 7 (P < 0Á05) and 30 days (P < 0Á0001) after hospitalization. No differences in length of stay or death status at discharge were observed.
We also observed significantly reduced readmission and acute care utilization among HC users according to medication adherence status. Patients who were more adherent to HC had significantly lower 7-day (P < 0Á0001) and 30-day (P < 0Á0001) readmission risks. High adherence to HC therapy (PDC ≥ 0Á80) was associated with a 13Á3% reduction (crude risk difference) in 30-day all-cause readmission, a 13Á1% SCD-related 30-day readmission and an 18Á3% 30-day acute care encounter (Table II) .
In multivariable-adjusted models, high (PDC ≥ 0Á80) and intermediate HC (0Á50 ≤ PDC < 0Á80) adherence were associated with lower 30-day all-cause readmission (OR, 0Á62; 95% CI 0Á47-0Á82, P = 0Á0007; and OR, 0Á62; 95% CI 0Á50-0Á75, P < 0Á0001, respectively) compared to HC users with low PDC (Table III) . In contrast, we did not observe any associations between HC exposure and readmission risks both in the whole analytical cohort and the adult subgroup when comparing HC users to never users. (See Tables SIV  and SV). HC was not approved by the US FDA for paediatric patients ages 2 years and older with SCD with recurrent moderate to severe painful crises until 21 December 2017 (US Food & Drug Administration 2017). In light of the differences in HC pharmacotherapy guidelines and SCD-related comorbidities in children and adults with SCD over the study period, we conducted subgroup analyses restricted to either paediatric (0-17 years of age at admission) and adult (18+ years at admission) SCD patients. In subgroup analyses limited to adult patients, we found that ≥1 g and 0Á5-1 g daily HC dose were associated with significant reduction in 30-day all-cause readmission risks as compared to 0-500 mg daily HC dose (OR, 0Á72; 95% CI 0Á52-0Á99, P = 0Á0451; and OR, 0Á73 95% CI 0Á57-0Á93, P = 0Á0122, respectively) (Table III) .
In subgroup analyses limited to paediatric SCD patients, multivariable generalised estimating equation regression models (data not shown) did not demonstrate any statistically significant relationship between adherence and the risk of inpatient readmission, acute care encounter or SCDrelated readmission events in the 7-and 30-day period after discharge.
Discussion
To our knowledge, this is the first large, population-based study to assess HC utilization patterns in relation to hospital readmissions and ER visits in a commercially-insured, nationally representative sample of SCD patients. We demonstrated substantial benefits in reducing 30-day SCD-related, all-cause readmission and acute care use attributable to adherent HC treatment and higher therapeutic dosage (average daily dose ≥1 g).
Readmission events in paediatric SCD patients are mainly attributed to vaso-occlusive crises (Panepinto et al, 2005; Ellison & Bauchner, 2007; Bou-Maroun et al, 2018) . Other factors, including older age, inpatient use of steroids, admission for pain without other SCD-related complications (Sobota et al, 2012) , absence of outpatient follow-up, concomitant asthma, oxygen within 24 h of discharge and disease severity, have been identified as risk factors for readmission in paediatric SCD patients (FreiJones et al, 2009) . Risk factors for readmission in adult patients with SCD differ in nature and include premature discharge, withdrawal syndromes, and recurrence of acute painful episodes (Ballas & Lusardi, 2005) . Another recent study identified absence of a listed primary care provider and the number of past hospitalizations for vaso-occlusive pain as significant risk factors for 30-day readmission (Brodsky et al, 2017) .
HC is a potent medication with proven efficacy and safety in clinical trials and observational studies. In a study of North Carolina Medicaid enrolees, adherence to HC therapy was demonstrated to reduce risks for inpatient and ER encounters in addition to a reduction in health care costs (Candrilli et al, 2011) . A cost-effectiveness study also showed statistically significant differences in healthcare expenditures attributable to HC therapy when compared to placebo (Moore et al, 2000) . While the potential benefits of HC treatment continue to be demonstrated, the adoption of this therapy in real-world practice settings can be slow and partly hampered by long-term safety concerns from both providers and families. In a study using a state administrative database, up to 70% of appropriate HC candidates were not taking the medication (Lanzkron et al, 2006) . A study has shown that worse Health Related Quality of Life (HRQoL) and worse fatigue were associated with poor adherence among adolescents and young adults (Badawy et al, 2017a) . Adherence to medication therapies like HC in SCD patients is a complex, multifactorial behaviour with negative beliefs, recall barriers and access barriers among the factors causing poor adherence to HC therapy (Badawy et al, 2017b) . In one study of 75 paediatric SCD cases, the adherence rate was 49% using pharmacy refill records while caregiver reported adherence ranged from 82% to 85% using visual analogue, modified Morisky scores or medical provider estimates (Thornburg et al, 2010) . These inconsistent findings based on measure of medication adherence are reflective of possible inaccuracies when relying on self-reported adherence measures alone and in paediatric SCD patients, where HC is dosed according to weight.
We observed lower adherence in adults compared to younger patients with SCD, highlighting the importance of care transition between paediatric and adult care providers. HC is demonstrated to be safe when children with SCD continue therapy through puberty and adulthood, with sustained haematological benefits and minimal safety concerns (Hankins et al, 2014) . Our findings support efforts to create a smoother transition to adult SCD care for adolescents on HC therapy.
The observed lower readmission risks in the HC unexposed patients probably reflect the unexposed group being composed of subjects with a mild or less severe form of SCD not indicated for HC therapy, representing potential confounding by disease severity or indication when making comparisons between SCD patients exposed to HC and those never receiving HC (Psaty et al, 1999) . Our results demonstrated that greater adoption of HC therapy has the potential to reduce SCD-related and all-cause readmissions and ER visits. Reducing acute care utilization without compromising SCD treatment outcomes would have substantial benefits to patients, their families, payers and society as a whole. Therefore, innovative strategies including adherence monitoring incorporating technological advances, education to the providers and caregivers, and psychological and social support programmes should be considered to improve adherence and optimal dosing of HC therapy.
Our study had several strengths worth noting. We utilized administrative pharmacy dispensing records to collect information on HC utilization patterns and adherence in combination with records of acute care encounters, methods that are well-established and reliably describe medication use in patients with pharmacy coverage and enrolled on US health plans (Boudreau et al, 2004a,b; Andrade et al, 2006) . Characterizing hospital encounters as a unique index enabled us to quantify the impacts of HC cumulative dose and adherence on readmission risks at a hospitalization event-level in a clinically meaningful way. In addition, by limiting the analysis to SCD-related admissions, we determined that our results were robust to differences in non-SCD-related hospitalization events. Thus, we attempted to maximize the internal and external validity of our findings. Several limitations should also be considered when interpreting our results. First, we used ICD-9-CM codes to identify medical conditions, an inherent limitation when using administrative health plan claims databases. We adopted a validated (RuSH) algorithm (Paulukonis et al, 2014) and a series of selection criteria to specify these conditions. Second, use of pharmacy dispensing records to evaluate medication adherence to HC therapy, while reproducible and not subject to recall bias, assumes that patients took the medication as directed. Also, we were unable to assess the reason for nonadherence to HC therapy. Poor adherence and early discontinuation to HC therapy could have been motivated by lack of treatment response. To address this, we employed more conservative measure of adherence (PDC) compared to other studies. Third, our study cohort consisted of commercially insured patients with SCD in the US with continuous health plan coverage which may differ from SCD patients that lack insurance or are publicly insured. Still, our study population is nationally-representative, including approximately 15% of overall SCD patients in the US. Finally, as in any observational study, while we measured many important clinical factors, potential bias from unmeasured confounding, such as weight and body mass index cannot be ruled out. Further studies are needed to confirm our findings and should include outcomes of mortality, end-organ damage and laboratory test changes to comprehensively evaluate the impact of poor adherence to HC therapy in SCD.
Conclusion
We demonstrated reduced 30-day SCD-related and all-cause readmission among adherent HC users. Our findings suggest that efforts to improve adherence and optimal dosing of HC in patients with SCD would be well motivated.
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